ECM
CLDX icon

Endurant Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Endurant Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,240
Closed -$469K – 81
2015
Q2 		$469K Sell
1,240
-2,493
-67% -$990K 0.14% 87
2015
Q1 		$1.56M Buy
+3,733
New +$1.34M 0.52% 59

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Endurant Capital Management's CLDX Position: Q3 2015 in Review

Endurant Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2015, closing a stake of 1,240 shares — an estimated $469K sold.

Endurant Capital Management first reported a position in CLDX in Q1 2015 and held it in 2 quarters. The position peaked at $1.56M in Q1 2015. 162 funds tracked by Wall St. Rank hold CLDX as of Q3 2015.

  • Endurant Capital Management reported no remaining Celldex Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Endurant Capital Management sold 1,240 Celldex Therapeutics shares in Q3 2015, an estimated $469K.
  • Endurant Capital Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 2 quarters.
  • Endurant Capital Management's Celldex Therapeutics position peaked at $1.56M in Q1 2015.
  • 162 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2015.

Based on Endurant Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.